Rockefeller Capital Management
PTCT icon

Rockefeller Capital Management’s PTC Therapeutics PTCT Stock Holding History

Rockefeller Capital Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.7M Sell
302,393
-82,279
-21% -$5.94M 0.04% 420
2026
Q1 		$26.2M Sell
384,672
-20,864
-5% -$1.48M 0.05% 372
2025
Q4 		$30.8M Sell
405,536
-68,222
-14% -$4.96M 0.06% 325
2025
Q3 		$29.1M Buy
473,758
+10,679
+2% +$556K 0.06% 312
2025
Q2 		$22.6M Buy
463,079
+7,751
+2% +$368K 0.05% 352
2025
Q1 		$23.2M Sell
455,328
-37,092
-8% -$1.85M 0.06% 316
2024
Q4 		$22.2M Sell
492,420
-1,168
-0.2% -$50K 0.06% 319
2024
Q3 		$18.3M Sell
493,588
-5,556
-1% -$186K 0.05% 367
2024
Q2 		$15.3M Sell
499,144
-1,072
-0.2% -$34.7K 0.04% 394
2024
Q1 		$14.6M Sell
500,216
-1,026
-0.2% -$28.7K 0.04% 408
2023
Q4 		$13.8M Buy
501,242
+123,183
+33% +$2.82M 0.05% 374
2023
Q3 		$8.47M Buy
378,059
+165,652
+78% +$6.16M 0.03% 464
2023
Q2 		$8.64M Buy
212,407
+22,434
+12% +$1.1M 0.03% 473
2023
Q1 		$9.2M Buy
189,973
+1,385
+0.7% +$63.3K 0.04% 432
2022
Q4 		$7.2M Buy
188,588
+34,446
+22% +$1.43M 0.04% 449
2022
Q3 		$7.74M Sell
154,142
-8,093
-5% -$397K 0.04% 424
2022
Q2 		$6.5M Buy
162,235
+14,917
+10% +$523K 0.03% 449
2022
Q1 		$5.5M Buy
147,318
+8,857
+6% +$341K 0.03% 527
2021
Q4 		$5.51M Buy
138,461
+7,721
+6% +$296K 0.03% 515
2021
Q3 		$4.86M Buy
130,740
+17,593
+16% +$723K 0.03% 491
2021
Q2 		$4.78M Buy
+113,147
New +$4.85M 0.03% 463
2020
Q4 		– Sell
-2,787
Closed -$130K – 2982
2020
Q3 		$130K Hold
2,787
– – ﹤0.01% 1173
2020
Q2 		$141K Sell
2,787
-610
-18% -$30K ﹤0.01% 1054
2020
Q1 		$152K Hold
3,397
– – ﹤0.01% 888
2019
Q4 		$163K Sell
3,397
-47
-1% -$2K ﹤0.01% 823
2019
Q3 		$116K Sell
3,444
-96
-3% -$4.18K ﹤0.01% 757
2019
Q2 		$159K Hold
3,540
– – ﹤0.01% 614
2019
Q1 		$133K Sell
3,540
-2,767
-44% -$92.9K ﹤0.01% 686
2018
Q4 		$216K Hold
6,307
– – ﹤0.01% 393
2018
Q3 		$296K Buy
+6,307
New +$261K ﹤0.01% 315

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Rockefeller Capital Management's PTCT Position: Q2 2026 in Review

Rockefeller Capital Management reduced its PTC Therapeutics (PTCT) stake by 21% in Q2 2026, selling an estimated $5.94M and leaving 302,393 shares worth $24.7M. The position accounts for 0.04% of the portfolio, ranked #420.

Rockefeller Capital Management first reported a position in PTCT in Q3 2018 and has held it in 30 quarters since. The position peaked at $30.8M in Q4 2025. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Rockefeller Capital Management held 302,393 shares of PTC Therapeutics worth $24.7M as of Q2 2026.
  • Rockefeller Capital Management sold 82,279 PTC Therapeutics shares in Q2 2026, an estimated $5.94M.
  • PTC Therapeutics made up 0.04% of Rockefeller Capital Management's portfolio in Q2 2026, its #420 holding.
  • Rockefeller Capital Management first reported a position in PTC Therapeutics in Q3 2018 and has held it in 30 quarters since.
  • Rockefeller Capital Management's PTC Therapeutics position peaked at $30.8M in Q4 2025.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.